Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Hypoglycemia Risk Trips Once-Weekly Insulin at AdComm

  • Post author:PacConAdmin
  • Post published:May 28, 2024
  • Post category:Uncategorized

An FDA advisory committee voted 7-4 that the risk of serious hypoglycemia seen with Novo Nordisk’s Awiqli insulin outweighed the convenience of its once-a-week dosing regimen for people with type…

Continue ReadingHypoglycemia Risk Trips Once-Weekly Insulin at AdComm

Louisiana Law Classifies Mifepristone and Misoprostol as Controlled Substances

  • Post author:PacConAdmin
  • Post published:May 28, 2024
  • Post category:Uncategorized

Believing “this bill protects women across Louisiana,” Gov. Jeff Landry on Friday signed state legislation classifying the abortion-inducing drugs mifepristone and misoprostol as controlled substances. Source: Drug Industry Daily

Continue ReadingLouisiana Law Classifies Mifepristone and Misoprostol as Controlled Substances

FDA Draft Guidance Seeks Comments on Drug Platform Tech Designation

  • Post author:PacConAdmin
  • Post published:May 28, 2024
  • Post category:Uncategorized

The FDA’s draft guidance on platform technology designations for drug development outlines how sponsors can submit a designation request and the benefits of the designation. Source: Drug Industry Daily

Continue ReadingFDA Draft Guidance Seeks Comments on Drug Platform Tech Designation

Lilly to Boost API Production for Tirzepatide and Pipeline Medicines

  • Post author:PacConAdmin
  • Post published:May 28, 2024
  • Post category:Uncategorized

Eli Lilly announced on Friday that it has more than doubled its investment in its Lebanon, Ind., manufacturing site with a $5.3 billion commitment that will expand its capacity to…

Continue ReadingLilly to Boost API Production for Tirzepatide and Pipeline Medicines

Colorectal Cancer Blood Test Gets AdComm OK as Primary Screening Tool

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

While Shield, Guardant’s blood-based colorectal cancer screening test, got an overall thumbs-up from an FDA advisory committee, members stressed that it’s no substitute for colonoscopy. Source: Drug Industry Daily

Continue ReadingColorectal Cancer Blood Test Gets AdComm OK as Primary Screening Tool

Dem Senators Urge FDA’s Califf to Reclaim Regulation of Lethal Injection Drugs

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

The FDA needs to regain the authority to regulate drugs used in executions, according to nine Democratic senators who Tuesday wrote separate letters to FDA Commissioner Robert Califf and Drug…

Continue ReadingDem Senators Urge FDA’s Califf to Reclaim Regulation of Lethal Injection Drugs

BioZorb Markers and Twin Tubes Get Recalls Designated Class I

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

Hologic BioZorb Markers with excessive adverse event reports and Vyaire Medical’s Twin Tube with the potential for the nozzle separating during patient use have been deemed as Class I recalls…

Continue ReadingBioZorb Markers and Twin Tubes Get Recalls Designated Class I

CDER Science, Research Efforts that Support Generics Detailed in 2023 Annual Report

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

The collaborative efforts that advance the development of more generic drugs is the work of CDER’s science and research program whose 2023 annual report provides details on the efforts behind…

Continue ReadingCDER Science, Research Efforts that Support Generics Detailed in 2023 Annual Report

Regulatory Update — Week of May 20, 2024

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

This week, the FDA issued a final rule reclassifying ultrasound cyclodestructive devices and published a notice seeking nominations for advisory panels of the Medical Devices Advisory Committee. Source: Drug Industry…

Continue ReadingRegulatory Update — Week of May 20, 2024

DC Circuit Upholds Ruling Allowing Drugmakers to Restrict Deliveries to Contract Pharmacies

  • Post author:PacConAdmin
  • Post published:May 23, 2024
  • Post category:Uncategorized

A federal appeals court has upheld a lower court ruling that the controversial 340B Drug Discount Program doesn’t stop drugmakers from restricting deliveries of discounted drugs to contract pharmacies. Source:…

Continue ReadingDC Circuit Upholds Ruling Allowing Drugmakers to Restrict Deliveries to Contract Pharmacies
  • Go to the previous page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 144
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company